Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Docetaxel in combination with Pertuzumab and Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description
Herceptin (trastuzumab) [product monograph]. HC. Health Canada approved trastuzumab in combination with pertuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Perjeta (pertuzumab) [product monograph]. HC. Health Canada approved pertuzumab in combination with trastuzumab and chemotherapy is indicated for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.
Perjeta (pertuzumab) [product monograph]. HC. Health Canada approved pertuzumab in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Phesgo (pertuzumab and trastuzumab) [product monograph]. HC. Health Canada approved pertuzumab and trastuzumab in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer.
Phesgo (pertuzumab and trastuzumab) [product monograph]. HC. Health Canada approved pertuzumab and trastuzumab in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC), who have not received prior anit-HER2 therapy or chemotherapy for metastatic disease.
Perjeta (pertuzumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pertuzumab in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Phesgo (pertuzumab and trastuzumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to Phesgo (pertuzumab and trastuzumab) in combination with docetaxel for the treatment of patients with HER2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.